Minervax

MinervaX is a healthcare startup focused on developing a maternal vaccine to combat Group B Streptococcus (GBS), a bacteria that can cause severe infections in newborns and adverse pregnancy outcomes. GBS is a common bacteria found in about 20% of pregnant women and is the leading cause of life-threatening infections in newborns in their first three months. It's responsible for a significant number of neonatal diseases, stillbirths, preterm deliveries, and long-term neurological damage in babies worldwide.

Currently, the prevention of GBS in newborns is a major vaccine objective identified by the US National Institute of Health. However, no universally effective vaccine has been approved yet. The existing intervention involves administering large amounts of preventative antibiotics to pregnant women, which has led to widespread antibiotic resistance and potential impacts on neonatal development.

MinervaX aims to address this issue by developing a vaccine based on adjuvanted proteins antigens that cover almost 100% of clinical GBS isolates. In simpler terms, the vaccine is designed to stimulate the body's immune response against GBS, providing protection to both the mother and the baby.

The company operates in the global healthcare market, specifically in the vaccine development sector. Its primary clients are healthcare providers who would administer the vaccine to pregnant women. MinervaX's business model revolves around the research, development, and eventual commercialization of this vaccine. The company would generate revenue through the sale of the vaccine to healthcare providers and institutions.

Keywords: MinervaX, maternal vaccine, Group B Streptococcus, GBS, neonatal infections, vaccine development, healthcare market, antibiotic resistance, adverse pregnancy outcomes, commercialization.